Head-to-head · Cost-Efficiency Index
NexLife vs Zeuss
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NexLife
Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Visit NexLifeZeuss
Patients already stable on a maintenance GLP-1 dose who want to pay per fill instead of a subscription.
Visit ZeussThe verdict
NexLife and Zeuss tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with NexLife (ranked #185, a hair above #186) — Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate. But Zeuss is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NexLife.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NexLife | Zeuss |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $165/mo (all doses, compounded) | $125/mo (starting dose, compounded) |
| Tirzepatide / mo | $215/mo (all doses, compounded) | $175/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,980 | $1,500 |
| Tirzepatide / yr (modeled) | $2,580 | $2,100 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #185 | #186 |
NexLife
63/100Where the value is
- Flat pricing confirmed at every dose for both drugs — no per-mg escalation during titration, unlike most compounded competitors in this batch
- LegitScript certified with a named medical director (Adam Kennah, M.D.)
- States every batch undergoes independent third-party testing for potency, sterility, pH, and endotoxin levels
The tradeoffs
- The commonly advertised '$186/mo' tirzepatide headline requires a 12-month commitment; the true no-commitment month-to-month price is $215/mo — about 16% more
- No individual compounding pharmacy is named, only 'LegitScript-certified, NABP-accredited' pharmacies generically
Regulatory note: the FDA issued a warning letter to Nexlife Inc. dba Nexlife in June 2026. We still list and link to NexLife; you should know the letter is on the public record before you decide.
Zeuss
63/100Where the value is
- Genuinely no-subscription billing confirmed in its own FAQ ('no recurring charges or automatic refills') — patients pay per order, not a locked recurring plan
- LegitScript certified, with the badge and verification link displayed on the homepage
- States it 'partners exclusively with 503A and 503B state-licensed compounding pharmacies'
The tradeoffs
- Both $125 and $175 are 'starting at' prices with no disclosed dose (mg) or confirmation the price holds at higher/titrated doses
- No compounding pharmacy is named, only 'licensed partner pharmacy'
Regulatory note: the FDA issued a warning letter to Zeuss LLC dba Zeuss in February 2026. We still list and link to Zeuss; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.